Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zi-long-jin tablets for maintenance treatment of advanced non-small cell lung cancer
ChiCTR1900027926Phase 4Not yet recruiting
- Sponsor
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Start
- Aug 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Zi-long-jin tablets in non-small cell lung cancer (NSCLC) (2 arms), sponsored by First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoints: Progression-free survival and Lung cancer-related quality of life score. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
Zi-long-jin tablets
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900027926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027926.